Greenleaf Trust Has $1.78 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Greenleaf Trust boosted its position in AstraZeneca PLC (NASDAQ:AZN) by 4.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 27,104 shares of the company’s stock after purchasing an additional 1,210 shares during the period. Greenleaf Trust’s holdings in AstraZeneca were worth $1,776,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC lifted its holdings in AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after buying an additional 258,477 shares during the period. Franklin Resources Inc. lifted its holdings in AstraZeneca by 8.7% in the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after buying an additional 1,522,715 shares during the period. Fisher Asset Management LLC lifted its holdings in AstraZeneca by 5.3% in the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after buying an additional 524,175 shares during the period. Manning & Napier Advisors LLC lifted its holdings in AstraZeneca by 17.7% in the fourth quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock valued at $245,407,000 after buying an additional 564,297 shares during the period. Finally, Bank of Montreal Can raised its holdings in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after purchasing an additional 1,605,758 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.7 %

NASDAQ:AZN opened at $70.76 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a 50-day moving average of $67.08 and a 200-day moving average of $73.89. The company has a market cap of $219.43 billion, a PE ratio of 33.86, a PEG ratio of 1.18 and a beta of 0.46. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.87 earnings per share. As a group, equities research analysts expect that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.